CIPO trademark

XYREM

RegisteredCIPOWord markClass 5

"XYREM" is a word mark owned by Jazz Pharmaceuticals, Inc., filed at the CIPO on June 8, 2006. It is registered and covers class 5 (Pharmaceuticals).

View Jazz Pharmaceuticals, Inc. portfolio Get this data via the API

Data current as of February 18, 2026Official CIPO record

XYREM

Word mark as filed with the CIPO

Status: Registered; Since February 18, 2010
Filed: June 8, 2006
Registered: February 18, 2010
Expires: February 18, 2035
Application no.: 1304721
Registration no.: TMA759794
Office: CIPO; Canadian Intellectual Property Office
Mark type: Word mark; 1 class

Ownership

Who owns XYREM

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Jazz Pharmaceuticals, Inc.

JAZZ · United States

25 trademarks in the portfolioView company

Representative

Gowling WLG (Canada) LLP

Goods and services

What the mark covers

The products and services XYREM is filed for, grouped by Nice class.

05Class 5 · Pharmaceuticals
Pain relief medication; preparation for the relief of pain; pharmaceutical preparations for the treatment of disorders affecting the central nervous system, namely drug and alcohol addiction, conduct disorder, oppositional defiant disorder, attention deficit disorders, amnestic disorders, autism, schizophrenia, psychosis, depression, chronic fatigue syndrome, anxiety, irritable bowel disorder, narcolepsy, fibromyalgia, insomnia, and myositis; pharmaceutical preparations for use in the treatment and management of sleep disorders, chronic fatigue syndrome, drug and alcohol abuse, anxiety, cerebrovascular diseases, neurological disorders, namely essential tremor, tic disorders, Tourette's syndrome, Parkinson's disease, Huntington's disease, restless leg syndrome, myoclonus, dystonias, dementia, Alzheimer's disease, learning disabilities, multiple sclerosis, sleep disorders, post surgical pain, post-trauma pain, neuropathic pain and diabetic pain, autism, depression, inflammatory disorders, namely inflammatory bowel disorder, regional ileitis, ulcerative colitis, irritable bowel disorder, autoimmune inflammatory disorders, endocrine disturbances, and diabetes; and pharmaceutical preparations for the purpose of tissue protection namely, tissue protection following hypoxia/anoxia as in the case of stroke, organ transplantation, organ preservation, myocardial infarction or ischemia, reperfusion injury, and protection following radiation, progeria, or an increased level of intracranial pressure as in the case of head trauma.; Pain relief medication; preparation for the relief of pain; pharmaceutical preparations for the treatment of disorders affecting the central nervous system, namely drug and alcohol addiction, depression, chronic fatigue syndrome, anxiety, narcolepsy, fibromyalgia, insomnia; pharmaceutical preparations for use in the treatment and management of sleep disorders, chronic fatigue syndrome, drug and alcohol abuse, neurological disorders, namely essential tremor, tic disorders, Tourette's syndrome, Parkinson's disease, Huntington's disease, restless leg syndrome, myoclonus, dystonias, Alzheimer's disease, sleep disorders, post surgical pain, post-trauma pain or neuropathic pain and diabetic pain.

History

What has happened so far

Steps recorded by the CIPO, newest first.

October 29, 2025Owner Address Change / Changement d'adresse du propriétaire
October 29, 2025Amendment to Registration; Address/address
March 25, 2025Nice Class(es) Acceptance Letter Sent
February 18, 2025Renewed; DP:2024/12/30 RD:2024/12/30 RR:(8390) GOWLING WLG (CANADA) LLP
August 16, 2019Agent Changed; From: 10425 To: 32 / Voir Preuve au dossier/See evidence on File No. 1355599
April 12, 2016Change of Title Registered; Assignment / Voir Preuve au dossier/See evidence on File No. 1304721
February 25, 2016FROM: JPI Commercial, LLC; a Delaware limited liability company; TO: Jazz Pharmaceuticals, Inc.; Voir Preuve au dossier/See evidence on File No. 1304721
February 18, 2010Registered
November 25, 2009Change of Title Registered; Assignment / Voir Preuve au dossier/See evidence on File No. 1023221
November 25, 2009Amendment to Application; Merger / Voir Preuve au dossier/See evidence on File No. 1023221

10 earlier steps on the official record.

FAQ

About XYREM

Who owns the trademark "XYREM"?

The CIPO trademark "XYREM" (application 1304721) is owned by Jazz Pharmaceuticals, Inc.

What is the status of "XYREM"?

Its status at the CIPO is: registered.

When was "XYREM" registered?

It was registered on February 18, 2010 and is due to expire on February 18, 2035.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull XYREM and marks like it into your own product with one request.

GET/v1/trademarks/{id}
The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/events
Every step in the office history
GET/v1/proceedings?trademark_id={id}
Oppositions and cancellations against the mark

Get API key View docs

GET /v1/trademarks/{id}

ID=tm_019deb59-9e59-7659-88ea-05197d70e611
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"

Response

{
  "id": "tm_019deb59-9e59-7659-88ea-05197d70e611",
  "object": "trademark",
  "mark_text": "XYREM",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "CA",
  "application_number": "1304721",
  "filing_date": "2006-06-08",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Jazz Pharmaceuticals, Inc.",
      "entity_id": "ent_019eb70a-222a-730c-802e-638eb3dd0000"
    }
  ]
}